Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Acetazolamide + OBX-115 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Acetazolamide | Acetamox | Acetamidothiadiazolesulfonamide | Acetazolamide is a sulfonomide that inhibits carbonic anhydrase, potentially resulting in increased tumor cell apoptosis and decreased tumor cell growth, alone and in combination with other agents (PMID: 29928333). | |
| OBX-115 | OBX 115|OBX115|CytoTIL15 | OBX-115 comprises tumor-infiltrating lymphocytes (TILs) engineered to express membrane-bound IL-15 (mbIL15), which potentially induce tumor cell killing and lead to antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 9515), NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05470283 | Phase I | Acetazolamide + OBX-115 Cyclophosphamide + Fludarabine + Furosemide + Mesna | Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma | Active, not recruiting | USA | 0 |